Skip to main content
argenx SE
Healthcare · Biotechnology
Made on Aug 16, 2026
Price at call $851.29
6-month call Bear -9.0%
Target by Feb 2027 $775.00
Great value below $575.00
Model v0.6.0

Projection vs Actual (6M history + forecast)

The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change -9.0% to $775.00
Predicted High $862.00 at 1 month
Predicted Low $775.00 at 6 months
Max Drawdown (predicted) -9.0%

Forecast

The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded. Predicted Aug 16, 2026 12:39 am
Bear ARGX trends lower to $775.00 (-9.0% from $851.29) by Feb 2027. ride-then-fade
ThesisARGX trades well above DCF and composite fair value but momentum, visionary-founder narrative, and consistent EPS beats sustain the premium near term; over 6 months value gravity and rate pressure drag price modestly lower toward the deterministic baseline without full mean reversion.
Invalidated ifA break above $920 on positive catalyst or below $720 on pipeline setback would falsify this glide path.
Checkpointtime after the call Datewhen it gets graded Predictedthe claim: closing price Current priceactual close — fills in over time Predicted returnpredicted vs $851.29 at call Conv.brain's confidence, 1–10 Driverwhy the brain put the point here
Prediction made Aug 16, 2026 $851.29 at call The anchor — every point below is measured from this price and date.
2 weeks Aug 30, 2026 $785.59–$916.99 typical range · internal point $858.00 ±7.7% 6/10 Risk-on regime and momentum extend recent bid
1 month Sep 16, 2026 $756.08–$946.50 typical range · internal point $862.00 ±11.2% 5/10 Narrative tailwind persists, no catalyst yet
2 months Oct 16, 2026 $845.00 -0.7% 5/10 Valuation gravity begins to weigh modestly
3 months Nov 16, 2026 $825.00 -3.1% 5/10 Premium compression as rate pressure lingers
4 months Dec 16, 2026 $805.00 -5.4% 4/10 Year-end rebalancing trims extended winners
5 months Jan 16, 2027 $785.00 -7.8% 4/10 Drift toward deterministic baseline continues
6 months Feb 16, 2027 $775.00 -9.0% 4/10 Path converges near baseline endpoint

Why ranges on the short rungs? A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here — three prompt formulations all lost to simply predicting zero — while the stock's own volatility scale (σ×√t) described those windows well. So the short rungs claim what's actually knowable: the typical travel, with earnings timing flagged where the variance will come from. The internal point calls keep being generated and graded to map where real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.

Deterministic control (v0.3 value line) targets $769.79 (-9.6%) — both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it. Brain: claude-opus-4-7.

Weaknesses

0 blocking · 1 degraded · 1 note — follow the chain top-down (cause → effect).
  • Degraded
    [critical] Cash flow quality is poor — reported earnings may not reflect reality
    upstream:valuation-synthesis
  • Note
    EPV de-weighted — growth IS the value proposition for this type of company
    upstream:classification

Equation Inputs

Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.

Value anchors (from deep analysis)

Price at call$851.29
Composite fair value$509.28
Signal-adjusted fair value$464.09
DCF fair value$247.73
Anchored-PE fair value$1,054.00
Buy-below (value lens)$575.00
Value net score-67
Value confidence7 / 10
Quality net score+41
Memo confidence7 / 10
Deserved value (base)
Quality tilt
Deserved value (used)
Coherence (value × quality)

Price behaviour (trailing — shapes the realism line)

Realized volatility (annualized) 1m 40.6%  3m 38.7%  6m 35.4%  
Daily σ (realism noise)2.4%
Beta vs S&P 500 1m -1.06  3m -0.29  5m 0.34  
Trailing 6-month return2.2%

Knobs (equation params)

ladderArray
llm_modelclaude-opus-4-7
max_tokens3000
control_knobsArray
Neutral band (%)5
earnings_briefv1
prompt_versionp1
control_versionv0.3.0

Version & Tech Chain

What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model v0.6.0 #271041f8fcd5

Tech composition (what this version is built from)

#ProcessKindGroup
1 Synthesis valuation-synthesis deterministic final
2 Scenario Analysis scenario-valuation deterministic valuation
3 Valuation / Mispricing ext-lens-value llm extended
4 Company Quality ext-lens-quality llm extended
5 Forensic Memo (combiner) ext-forensic-memo llm extended
6 Classification company-classification llm foundation
7 Live Quote fmp-quote data market-data

Inputs used (the runs that fed this prediction)

Upstream processRanLagRun id
company-classification Aug 16, 2026 freshest ARGX-20260816-000949-2cbf
ext-forensic-memo Aug 16, 2026 freshest ext-ARGX-20260816-002937-baf5
ext-lens-quality Aug 16, 2026 freshest ext-ARGX-20260816-002937-baf5
ext-lens-sentiment Aug 16, 2026 freshest ext-ARGX-20260816-002937-baf5
ext-lens-value Aug 16, 2026 freshest ext-ARGX-20260816-002937-baf5
scenario-valuation Aug 16, 2026 freshest ARGX-20260816-000949-2cbf
valuation-synthesis Aug 16, 2026 freshest ARGX-20260816-000949-2cbf

Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.

Saved History

2 frozen snapshots — the record we score once predictions mature.
MadeModelCallAt callTargetExp.Eval due
Aug 16, 2026 v0.6.0 Bear $851.29 $775.00 -9.0% Feb 2027 viewing
Jul 21, 2026 v0.3.0 view

Not Yet Modeled

What this v0.6.0 forecast deliberately ignores — the work ahead, in plain sight.
  • Scenario probabilities — one path, no bull/bear split (base_prob = 1.0).
  • Intraday / sub-2-week behaviour — the first claim is at 14 days by design (EOD product).
  • Position sizing / portfolio context — the path is a price claim only.